C G Kryh1, C A Pietersen2, H B Rahr3, R D Christensen4, P Wamberg5, M D Lautrup6. 1. Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: c.kryh@hotmail.com. 2. Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: cpietersen@yahoo.com. 3. Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: hans.rahr@slb.regionsyddanmark.dk. 4. Research Unit of General Practice, J.B. Winsloews Vej 9, 5000 Odense C, Denmark. Electronic address: depont42@gmail.com. 5. Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: peter.arne.wamberg@region.syddanmark.dk. 6. Department of Breast Surgery, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark. Electronic address: marianne.korsgaard@dadlnet.dk.
Abstract
OBJECTIVES: To examine the frequency of re-resections and describe risk characteristics: invasive carcinoma or carcinoma in situ (CIS), palpability of the lesion, and neoadjuvant chemotherapy. RESULTS: 1703 breast conserving surgeries were performed: 1575 primary breast conserving surgeries (BCS), and 128 diagnostic excisions (DE). 176 BCS (11.2% [9.6; 12.7]) and 100 DE had inadequate margins indicating re-resection. The overall re-resection rate was 16.2% [14.5; 18.0]. 10.3% of invasive carcinoma BCS patients, and 28.6% CIS patients underwent re-resection (relative risk (RR) 2.8 [1.9; 4.1]). Invasive lobular carcinoma (ilc) had an RR of re-resection of 2.5 [1.7; 3.8], compared with invasive ductal carcinoma (idc). CONCLUSION: Overall 11.2% of the BCS patients needed a re-resection. For isolated CIS (28.6%), RR of re-resection was almost three times as high compared to invasive carcinoma (10.3%). Ilc had an RR of re-resection of 2.5 compared to idc. Palpability and neoadjuvant chemotherapy did not significantly influence the risk of re-resection.
OBJECTIVES: To examine the frequency of re-resections and describe risk characteristics: invasive carcinoma or carcinoma in situ (CIS), palpability of the lesion, and neoadjuvant chemotherapy. RESULTS: 1703 breast conserving surgeries were performed: 1575 primary breast conserving surgeries (BCS), and 128 diagnostic excisions (DE). 176 BCS (11.2% [9.6; 12.7]) and 100 DE had inadequate margins indicating re-resection. The overall re-resection rate was 16.2% [14.5; 18.0]. 10.3% of invasive carcinoma BCSpatients, and 28.6% CIS patients underwent re-resection (relative risk (RR) 2.8 [1.9; 4.1]). Invasive lobular carcinoma (ilc) had an RR of re-resection of 2.5 [1.7; 3.8], compared with invasive ductal carcinoma (idc). CONCLUSION: Overall 11.2% of the BCS patients needed a re-resection. For isolated CIS (28.6%), RR of re-resection was almost three times as high compared to invasive carcinoma (10.3%). Ilc had an RR of re-resection of 2.5 compared to idc. Palpability and neoadjuvant chemotherapy did not significantly influence the risk of re-resection.
Authors: J M Escribà; L Esteban; J Gálvez; M J Pla; A Melià; M Gil-Gil; R Clèries; L Pareja; X Sanz; M Bustins; J M Borrás; J Ribes Journal: Clin Transl Oncol Date: 2016-09-13 Impact factor: 3.405
Authors: Julieta Politi; María Sala; Laia Domingo; María Vernet-Tomas; Marta Román; Francesc Macià; Xavier Castells Journal: Womens Health (Lond) Date: 2020 Jan-Dec
Authors: José H Volders; Vera L Negenborn; Pauline E Spronk; Nicole M A Krekel; Linda J Schoonmade; Sybren Meijer; Isabel T Rubio; M Petrousjka van den Tol Journal: Breast Cancer Res Treat Date: 2017-12-06 Impact factor: 4.872
Authors: Chong Zhang; Daqing Jiang; Bo Huang; Cong Wang; Lin Zhao; Xianxin Xie; Zhaohe Zhang; Kun Wang; Jie Tian; Yahong Luo Journal: Technol Cancer Res Treat Date: 2019 Jan-Dec